About FibroGen (NASDAQ:FGEN)

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200
Debt
Debt-to-Equity Ratio0.17%
Current Ratio9.70%
Quick Ratio9.70%
Price-To-Earnings
Trailing P/E Ratio-26.82
Forward P/E Ratio-34.37
P/E GrowthN/A
Sales & Book Value
Annual Sales$125.67 million
Price / Sales30.52
Cash FlowN/A
Price / CashN/A
Book Value$7.09 per share
Price / Book6.54
Profitability
EPS (Most Recent Fiscal Year)($1.73)
Net Income$-126,200,000.00
Net Margins-100.43%
Return on Equity-32.08%
Return on Assets-18.17%
Miscellaneous
Employees423
Outstanding Shares82,670,000
FibroGen (NASDAQ:FGEN) Frequently Asked Questions
What is FibroGen's stock symbol?
FibroGen trades on the NASDAQ under the ticker symbol "FGEN."
How were FibroGen's earnings last quarter?
FibroGen (NASDAQ:FGEN) released its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.28) by $0.01. The biopharmaceutical company earned $42.51 million during the quarter, compared to analyst estimates of $45.37 million. FibroGen had a negative return on equity of 32.08% and a negative net margin of 100.43%. View FibroGen's Earnings History.
When is FibroGen's next earnings date?
What price target have analysts set for FGEN?
7 analysts have issued 1-year price targets for FibroGen's stock. Their forecasts range from $31.00 to $88.00. On average, they expect FibroGen's stock price to reach $66.6667 in the next year. View Analyst Ratings for FibroGen.
What are Wall Street analysts saying about FibroGen stock?
Here are some recent quotes from research analysts about FibroGen stock:
- 1. According to Zacks Investment Research, "FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. " (3/5/2018)
- 2. Mizuho analysts commented, "We believe Fibrogen is fairly priced. KeyPoints Earnings. For 3Q17, Fibrogen’s financials missed street estimates on reported revenue of $27.3 mil vs. consensus of $39.7 mil and missed on reported EPS of $(0.50) vs. consensus of $(0.37). License and milestone revenue recognized in the quarter appeared lower than expectations. R&D and SG&A expenses were approximately in-line with our prior projections. For 4Q17, Fibrogen expects to recognize a $15 mil milestone from AstraZeneca (AZN, not rated) related to roxadustat’s NDA filing in October 2017 in China. Quarterly earnings are usually not a driver for development stage companies like Fibrogen. In our opinion, news flow related to the pipeline development are more likely to be a catalyst. Progress for pamrevlumab in IPF. During the quarter Fibrogen reported positive topline results from their phase II trial for pamrevlumab in moderate- to-severe idiopathic pulmonary fibrosis (IPF) patients." (11/9/2017)
Who are some of FibroGen's key competitors?
Some companies that are related to FibroGen include Alkermes (ALKS), Valeant Pharmaceuticals International (VRX), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), GW Pharmaceuticals (GWPH), Blueprint Medicines (BPMC), Advanced Accelerator Application (AAAP), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY) and Tesaro (TSRO).
Who are FibroGen's key executives?
FibroGen's management team includes the folowing people:
- Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 64)
- Mr. Pat Cotroneo, VP of Fin. & CFO (Age 54)
- Dr. K. Peony Yu M.D., Chief Medical Officer (Age 56)
- Dr. Barry A. Berkowitz, Founder
- Dr. Michael J. Martinelli Ph.D., VP of Technical Devel.
When did FibroGen IPO?
(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.
Has FibroGen been receiving favorable news coverage?
Media headlines about FGEN stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. FibroGen earned a media sentiment score of 0.14 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.91 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of FibroGen?
Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is FibroGen's stock price today?
One share of FGEN stock can currently be purchased for approximately $46.40.
How big of a company is FibroGen?
FibroGen has a market capitalization of $3.85 billion and generates $125.67 million in revenue each year. The biopharmaceutical company earns $-126,200,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. FibroGen employs 423 workers across the globe.
How can I contact FibroGen?
FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]
MarketBeat Community Rating for FibroGen (FGEN)
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
FibroGen (NASDAQ:FGEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for FibroGen in the last 12 months. Their average twelve-month price target is $66.6667, suggesting that the stock has a possible upside of 43.68%. The high price target for FGEN is $88.00 and the low price target for FGEN is $31.00. There are currently 2 hold ratings, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
Consensus Rating: | Buy | Buy | Buy | Buy |
Consensus Rating Score: | 2.86 | 2.86 | 2.86 | 2.88 |
Ratings Breakdown: | 0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 1 Strong Buy Rating(s) | 0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 1 Strong Buy Rating(s) | 0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 1 Strong Buy Rating(s) | 0 Sell Rating(s) 2 Hold Rating(s) 5 Buy Rating(s) 1 Strong Buy Rating(s) |
Consensus Price Target: | $66.6667 | $66.6667 | $65.6667 | $65.6667 |
Price Target Upside: | 43.68% upside | 14.06% upside | 21.49% upside | 9.26% upside |
FibroGen (NASDAQ:FGEN) Consensus Price Target History

FibroGen (NASDAQ:FGEN) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
FibroGen (NASDAQ:FGEN) Dividend History by Quarter
Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
---|
(Data available from 1/1/2013 forward)
FibroGen (NASDAQ FGEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.60%
Institutional Ownership Percentage: 61.39%
FibroGen (NASDAQ FGEN) Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
4/19/2018 | Kalevi Kurkijarvi | Director | Sell | 4,000 | $47.69 | $190,760.00 | 24,000 | |
4/18/2018 | Thomas B Neff | CEO | Sell | 39,636 | $48.56 | $1,924,724.16 | 2,933,653 | |
4/16/2018 | K Peony Yu | Insider | Sell | 7,500 | $47.81 | $358,575.00 | 156,233 | |
4/9/2018 | Jorma Routti | Director | Sell | 6,000 | $46.59 | $279,540.00 | 133,840 | |
4/5/2018 | Thomas B Neff | CEO | Sell | 39,636 | $45.59 | $1,807,005.24 | 2,950,813 | |
3/21/2018 | Thomas B Neff | CEO | Sell | 39,636 | $50.95 | $2,019,454.20 | 2,969,251 | |
3/15/2018 | Pat Cotroneo | VP | Sell | 42,026 | $52.85 | $2,221,074.10 | 168,334 | |
3/15/2018 | Roberto Pedro Rosenkranz | Director | Sell | 1,000 | $52.34 | $52,340.00 | 24,000 | |
3/14/2018 | K Peony Yu | Insider | Sell | 9,891 | $53.20 | $526,201.20 | 128,333 | |
3/13/2018 | Pat Cotroneo | CFO | Sell | 5,932 | $54.61 | $323,946.52 | 168,334 | |
3/12/2018 | Thomas F Kearns Jr | Director | Sell | 18,000 | $55.00 | $990,000.00 | 135,064 | |
3/9/2018 | Rory B Riggs | Director | Sell | 22,905 | $55.75 | $1,276,953.75 | 411,295 | |
3/8/2018 | Pat Cotroneo | VP | Sell | 1,894 | $53.12 | $100,609.28 | 176,160 | |
3/8/2018 | Thomas B Neff | CEO | Sell | 39,636 | $53.14 | $2,106,257.04 | 2,907,425 | |
2/23/2018 | Thomas B Neff | CEO | Sell | 39,636 | $56.66 | $2,245,775.76 | 2,955,614 | |
2/16/2018 | Pat Cotroneo | VP | Sell | 49,500 | $55.96 | $2,770,020.00 | 207,392 | |
2/15/2018 | Kalevi Kurkijarvi | Director | Sell | 6,000 | $55.69 | $334,140.00 | 26,000 | |
2/8/2018 | K Peony Yu | Insider | Sell | 7,500 | $53.97 | $404,775.00 | 144,986 | |
1/30/2018 | Thomas B Neff | CEO | Sell | 38,636 | $61.40 | $2,372,250.40 | 2,958,105 | |
1/29/2018 | K Peony Yu | Insider | Sell | 10,000 | $62.00 | $620,000.00 | 152,086 | |
1/26/2018 | Roberto Pedro Rosenkranz | Director | Sell | 6,000 | $60.00 | $360,000.00 | 29,000 | |
1/22/2018 | Pat Cotroneo | CFO | Sell | 25,000 | $48.72 | $1,218,000.00 | 208,852 | |
1/22/2018 | Roberto Pedro Rosenkranz | Director | Sell | 71 | $50.00 | $3,550.00 | 36,929 | |
1/18/2018 | Kalevi Kurkijarvi | Director | Sell | 6,000 | $47.38 | $284,280.00 | 28,000 | |
1/18/2018 | Thomas B Neff | CEO | Sell | 18,900 | $47.64 | $900,396.00 | 2,981,447 | |
1/5/2018 | Thomas B Neff | CEO | Sell | 38,636 | $47.61 | $1,839,459.96 | 3,029,887 | |
12/29/2017 | Thomas B Neff | CEO | Sell | 38,636 | $48.39 | $1,869,596.04 | | |
12/28/2017 | Thomas B Neff | CEO | Sell | 18,900 | $48.29 | $912,681.00 | 3,071,705 | |
12/21/2017 | Thomas B Neff | CEO | Sell | 38,636 | $44.66 | $1,725,483.76 | 3,022,934 | |
12/18/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $42.80 | $85,600.00 | 22,000 | |
12/14/2017 | K Peony Yu | Insider | Sell | 2,851 | $43.70 | $124,588.70 | 162,086 | |
12/14/2017 | Thomas B Neff | CEO | Sell | 18,900 | $42.71 | $807,219.00 | 3,060,887 | |
12/12/2017 | Kalevi Kurkijarvi | Director | Sell | 12,000 | $44.45 | $533,400.00 | 36,000 | |
12/11/2017 | Pat Cotroneo | VP | Sell | 2,851 | $46.00 | $131,146.00 | 183,852 | |
12/4/2017 | Gerald Lema | Director | Buy | 3,500 | $46.70 | $163,450.00 | 3,500 | |
12/1/2017 | Jorma Routti | Director | Sell | 12,000 | $47.25 | $567,000.00 | 133,840 | |
11/17/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $46.65 | $93,300.00 | 24,000 | |
11/16/2017 | Thomas B Neff | CEO | Sell | 18,900 | $46.60 | $880,740.00 | 3,109,555 | |
11/15/2017 | Thomas F Kearns Jr | Director | Sell | 18,000 | $45.22 | $813,960.00 | 156,564 | |
11/6/2017 | K Peony Yu | Insider | Sell | 7,500 | $55.37 | $415,275.00 | 170,104 | |
10/31/2017 | Thomas B Neff | CEO | Sell | 38,636 | $56.13 | $2,168,638.68 | 3,144,573 | |
10/17/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $52.24 | $104,480.00 | 26,000 | |
10/17/2017 | Thomas B Neff | CEO | Sell | 38,636 | $55.02 | $2,125,752.72 | 3,176,861 | |
10/16/2017 | Thomas B Neff | CEO | Sell | 18,900 | $54.83 | $1,036,287.00 | 3,176,861 | |
10/4/2017 | K Peony Yu | Insider | Sell | 15,000 | $60.00 | $900,000.00 | | |
10/3/2017 | Thomas B Neff | CEO | Sell | 38,636 | $55.09 | $2,128,457.24 | | |
10/2/2017 | K Peony Yu | Insider | Sell | 40,000 | $54.63 | $2,185,200.00 | | |
10/2/2017 | Thomas B Neff | CEO | Sell | 18,900 | $54.45 | $1,029,105.00 | 3,217,455 | |
9/20/2017 | Thomas B Neff | CEO | Sell | 38,636 | $53.46 | $2,065,480.56 | 3,246,754 | |
9/18/2017 | Kalevi Kurkijarvi | Director | Sell | 4,000 | $46.65 | $186,600.00 | 30,000 | |
9/14/2017 | K Peony Yu | Insider | Sell | 2,851 | $51.00 | $145,401.00 | 185,546 | |
9/14/2017 | Thomas B Neff | CEO | Sell | 38,636 | $51.67 | $1,996,322.12 | 3,297,655 | |
9/13/2017 | Rory B Riggs | Director | Sell | 25,000 | $51.92 | $1,298,000.00 | 435,200 | |
9/13/2017 | Thomas B Neff | CEO | Sell | 18,900 | $51.29 | $969,381.00 | 3,297,655 | |
9/11/2017 | Pat Cotroneo | VP | Sell | 2,851 | $49.45 | $140,981.95 | 157,405 | |
9/1/2017 | Jorma Routti | Director | Sell | 12,000 | $47.36 | $568,320.00 | 133,840 | |
8/29/2017 | Thomas B Neff | CEO | Sell | 38,636 | $43.73 | $1,689,552.28 | 3,330,780 | |
8/28/2017 | Thomas B Neff | CEO | Sell | 18,900 | $43.04 | $813,456.00 | 3,330,780 | |
8/21/2017 | K Peony Yu | Insider | Sell | 7,500 | $41.03 | $307,725.00 | 191,507 | |
8/17/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $40.74 | $81,480.00 | 30,000 | |
8/8/2017 | K Peony Yu | Insider | Sell | 37,500 | $50.58 | $1,896,750.00 | 236,507 | |
8/8/2017 | Pat Cotroneo | VP | Sell | 95,000 | $50.61 | $4,807,950.00 | 173,366 | |
8/2/2017 | Pat Cotroneo | VP | Sell | 28,346 | $33.97 | $962,913.62 | 170,666 | |
8/1/2017 | K Peony Yu | Insider | Sell | 10,000 | $33.48 | $334,800.00 | 226,507 | |
7/25/2017 | Thomas B Neff | CEO | Sell | 38,636 | $35.09 | $1,355,737.24 | 3,330,780 | |
7/24/2017 | Thomas B Neff | CEO | Sell | 18,900 | $35.06 | $662,634.00 | 3,330,780 | |
7/17/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $33.45 | $66,900.00 | 32,000 | |
7/10/2017 | K Peony Yu | Insider | Sell | 5,000 | $32.98 | $164,900.00 | 216,507 | |
7/7/2017 | Thomas B Neff | CEO | Sell | 38,636 | $33.38 | $1,289,669.68 | 3,330,780 | |
7/6/2017 | Pat Cotroneo | VP | Sell | 4,000 | $34.00 | $136,000.00 | 167,366 | |
7/6/2017 | Thomas B Neff | CEO | Sell | 18,900 | $33.53 | $633,717.00 | 3,330,780 | |
6/22/2017 | Pat Cotroneo | VP | Sell | 3,000 | $32.00 | $96,000.00 | 166,366 | |
6/22/2017 | Thomas B Neff | CEO | Sell | 38,636 | $31.52 | $1,217,806.72 | 3,330,780 | |
6/19/2017 | Pat Cotroneo | VP | Sell | 5,500 | $30.00 | $165,000.00 | 168,866 | |
6/16/2017 | Thomas B Neff | CEO | Sell | 38,636 | $29.40 | $1,135,898.40 | 3,330,780 | |
6/15/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $28.50 | $57,000.00 | 34,000 | |
6/14/2017 | K Peony Yu | Insider | Sell | 3,721 | $28.95 | $107,722.95 | 221,507 | |
6/12/2017 | Pat Cotroneo | VP | Sell | 2,891 | $28.75 | $83,116.25 | 163,366 | |
6/12/2017 | Toshinari Tamura | Director | Sell | 30,000 | $28.89 | $866,700.00 | 60,000 | |
6/6/2017 | Thomas F Kearns Jr | Director | Sell | 18,000 | $28.71 | $516,780.00 | 156,564 | |
5/31/2017 | Thomas B Neff | CEO | Sell | 38,636 | $26.21 | $1,012,649.56 | 3,345,941 | |
5/16/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $27.40 | $54,800.00 | 36,000 | |
5/16/2017 | Thomas B Neff | CEO | Sell | 38,636 | $27.70 | $1,070,217.20 | 3,345,941 | |
5/15/2017 | Thomas B Neff | CEO | Sell | 18,900 | $27.75 | $524,475.00 | 3,345,941 | |
5/10/2017 | K Peony Yu | Insider | Sell | 5,000 | $26.38 | $131,900.00 | 227,346 | |
4/25/2017 | K Peony Yu | Insider | Sell | 5,000 | $28.00 | $140,000.00 | 236,046 | |
4/25/2017 | Pat Cotroneo | VP | Sell | 6,500 | $28.00 | $182,000.00 | 164,405 | |
4/25/2017 | Thomas B Neff | CEO | Sell | 38,636 | $26.92 | $1,040,081.12 | 3,345,941 | |
4/24/2017 | Thomas B Neff | CEO | Sell | 18,900 | $26.35 | $498,015.00 | 3,345,941 | |
4/17/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $25.25 | $50,500.00 | 38,000 | |
4/13/2017 | Thomas B Neff | CEO | Sell | 38,636 | $24.79 | $957,786.44 | 3,345,941 | |
4/4/2017 | Thomas B Neff | CEO | Sell | 38,636 | $23.92 | $924,173.12 | 3,345,941 | |
3/21/2017 | Thomas B Neff | CEO | Sell | 38,636 | $24.34 | $940,400.24 | 3,345,941 | |
3/20/2017 | Thomas B Neff | CEO | Sell | 18,900 | $24.88 | $470,232.00 | 3,345,941 | |
3/15/2017 | Thomas B Neff | CEO | Sell | 38,636 | $25.07 | $968,604.52 | 3,353,983 | |
2/16/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $24.45 | $48,900.00 | 40,000 | |
2/14/2017 | Thomas B Neff | CEO | Sell | 38,636 | $23.94 | $924,945.84 | 3,274,061 | |
2/13/2017 | Thomas B Neff | CEO | Sell | 18,900 | $23.97 | $453,033.00 | 3,274,061 | |
2/9/2017 | Thomas B Neff | CEO | Sell | 37,798 | $23.46 | $886,741.08 | 3,278,868 | |
1/27/2017 | Thomas B Neff | CEO | Sell | 37,798 | $23.29 | $880,315.42 | 3,288,484 | |
1/19/2017 | Kalevi Kurkijarvi | Director | Sell | 2,000 | $24.90 | $49,800.00 | 42,000 | |
1/12/2017 | Thomas B Neff | CEO | Sell | 37,798 | $23.85 | $901,482.30 | 3,298,100 | |
1/11/2017 | Pat Cotroneo | VP | Sell | 6,500 | $24.00 | $156,000.00 | 138,748 | |
1/10/2017 | K Peony Yu | Insider | Sell | 5,000 | $23.56 | $117,800.00 | 202,448 | |
12/28/2016 | Thomas B Neff | CEO | Sell | 37,798 | $20.74 | $783,930.52 | 3,307,718 | |
12/16/2016 | Rory B Riggs | Director | Sell | 20,000 | $20.87 | $417,400.00 | 460,200 | |
12/13/2016 | Thomas B Neff | CEO | Sell | 37,798 | $21.24 | $802,829.52 | 3,317,334 | |
12/12/2016 | Pat Cotroneo | VP | Sell | 2,344 | $22.05 | $51,685.20 | 132,248 | |
12/12/2016 | Thomas B Neff | CEO | Sell | 18,899 | $21.48 | $405,950.52 | 3,317,334 | |
11/29/2016 | Thomas B Neff | CEO | Sell | 37,798 | $22.80 | $861,794.40 | 3,331,639 | |
11/28/2016 | Thomas B Neff | CEO | Sell | 18,899 | $22.74 | $429,763.26 | 3,331,639 | |
11/18/2016 | Thomas F Kearns Jr | Director | Sell | 18,000 | $22.40 | $403,200.00 | 165,564 | |
11/17/2016 | Thomas B Neff | CEO | Sell | 37,798 | $22.29 | $842,517.42 | 3,341,255 | |
11/1/2016 | Thomas B Neff | CEO | Sell | 37,798 | $16.76 | $633,494.48 | 3,350,871 | |
10/19/2016 | Thomas B Neff | CEO | Sell | 37,798 | $17.75 | $670,914.50 | 3,360,487 | |
10/18/2016 | Thomas B Neff | CEO | Sell | 18,899 | $17.94 | $339,048.06 | 3,360,487 | |
10/4/2016 | Thomas B Neff | CEO | Sell | 18,899 | $20.67 | $390,642.33 | 3,370,103 | |
10/3/2016 | Thomas B Neff | CEO | Sell | 18,899 | $20.55 | $388,374.45 | 3,370,103 | |
9/21/2016 | Thomas B Neff | CEO | Sell | 37,798 | $21.66 | $818,704.68 | 3,379,719 | |
9/14/2016 | K Peony Yu | Insider | Sell | 2,345 | $18.66 | $43,757.70 | 206,502 | |
9/12/2016 | Pat Cotroneo | VP | Sell | 2,345 | $18.22 | $42,725.90 | 134,359 | |
9/9/2016 | Thomas B Neff | CEO | Sell | 37,798 | $18.99 | $717,784.02 | 3,389,335 | |
8/26/2016 | Thomas B Neff | CEO | Sell | 37,798 | $17.80 | $672,804.40 | 3,403,639 | |
7/27/2016 | Thomas B Neff | CEO | Sell | 37,798 | $18.38 | $694,727.24 | 3,413,255 | |
7/13/2016 | Thomas B Neff | CEO | Sell | 27,000 | $17.50 | $472,500.00 | 3,412,664 | |
6/29/2016 | Thomas B Neff | CEO | Sell | 27,000 | $16.02 | $432,540.00 | 3,439,764 | |
6/15/2016 | Pat Cotroneo | CFO | Sell | 1,796 | $16.49 | $29,616.04 | 138,114 | |
6/15/2016 | Thomas B Neff | CEO | Sell | 27,000 | $16.48 | $444,960.00 | 3,466,664 | |
6/10/2016 | K Peony Yu | Insider | Sell | 2,344 | $17.96 | $42,098.24 | 210,257 | |
6/3/2016 | Thomas B Neff | CEO | Sell | 27,000 | $18.99 | $512,730.00 | 3,507,164 | |
5/20/2016 | Thomas B Neff | CEO | Sell | 27,000 | $17.68 | $477,360.00 | 3,526,053 | |
5/16/2016 | Pat Cotroneo | CFO | Sell | 6,107 | $17.60 | $107,483.20 | 141,868 | |
5/3/2016 | Thomas B Neff | CEO | Sell | 27,000 | $17.78 | $480,060.00 | 3,552,353 | |
4/20/2016 | Thomas B Neff | CEO | Sell | 27,000 | $19.98 | $539,460.00 | 3,579,353 | |
4/19/2016 | Thomas B Neff | CEO | Sell | 13,500 | $20.21 | $272,835.00 | 3,579,353 | |
4/5/2016 | Thomas B Neff | CEO | Sell | 27,000 | $21.11 | $569,970.00 | 3,606,353 | |
4/1/2016 | Frank H Md Valone | Insider | Sell | 10,750 | $21.11 | $226,932.50 | 115,434 | |
3/22/2016 | Thomas B Neff | CEO | Sell | 27,000 | $18.74 | $505,980.00 | 3,633,453 | |
3/8/2016 | Thomas B Neff | CEO | Sell | 27,000 | $19.62 | $529,740.00 | 3,667,175 | |
3/1/2016 | Frank H Md Valone | Insider | Sell | 10,750 | $16.84 | $181,030.00 | 115,133 | |
2/23/2016 | Thomas B Neff | CEO | Sell | 27,000 | $19.11 | $515,970.00 | 3,596,207 | |
2/22/2016 | Thomas B Neff | CEO | Sell | 13,500 | $19.81 | $267,435.00 | 3,596,207 | |
2/16/2016 | Frank H. Md Valone | insider | Sell | 10,750 | $18.41 | $197,907.50 | 96,840 | |
2/10/2016 | Thomas B. Neff | CEO | Sell | 27,000 | $15.31 | $413,370.00 | 3,609,407 | |
1/29/2016 | Thomas B. Neff | CEO | Sell | 27,000 | $19.41 | $524,070.00 | 3,636,407 | |
1/21/2016 | Thomas F Kearns Jr | Director | Sell | 1,572 | $22.08 | $34,709.76 | 160,564 | |
1/14/2016 | Thomas B. Neff | CEO | Sell | 27,000 | $23.69 | $639,630.00 | 3,663,407 | |
12/24/2015 | Thomas F. Kearns, Jr. | Director | Sell | 7,800 | $30.88 | $240,864.00 | 162,136 | |
12/23/2015 | Thomas B. Neff | CEO | Sell | 27,000 | $30.10 | $812,700.00 | 3,690,407 | |
12/11/2015 | Thomas B. Neff | CEO | Sell | 27,000 | $29.59 | $798,930.00 | 3,717,407 | |
12/10/2015 | K Peony Yu | VP | Sell | 1,093 | $28.96 | $31,653.28 | 176,595 | |
12/8/2015 | Miguel Madero | Director | Sell | 40,386 | $30.49 | $1,231,369.14 | 55,614 | |
11/30/2015 | K Peony Yu | VP | Sell | 5,000 | $30.00 | $150,000.00 | 178,345 | |
11/25/2015 | Pat Cotroneo | CFO | Sell | 5,000 | $30.00 | $150,000.00 | 107,775 | |
11/24/2015 | Thomas B. Neff | CEO | Sell | 13,500 | $28.98 | $391,230.00 | 3,746,689 | |
11/24/2015 | Thomas F. Kearns, Jr. | Director | Sell | 3,900 | $29.00 | $113,100.00 | 169,936 | |
11/23/2015 | Thomas B. Neff | CEO | Sell | 13,500 | $27.99 | $377,865.00 | 3,746,689 | |
11/23/2015 | Thomas F. Kearns, Jr. | Director | Sell | 3,900 | $28.02 | $109,278.00 | 169,936 | |
11/17/2015 | K Peony Yu | VP | Sell | 5,000 | $28.00 | $140,000.00 | 183,345 | |
11/10/2015 | K Peony Yu | VP | Sell | 5,000 | $25.62 | $128,100.00 | 187,904 | |
11/9/2015 | K Peony Yu | VP | Sell | 2,500 | $25.00 | $62,500.00 | 187,904 | |
11/2/2015 | Frank H. Md Valone | insider | Sell | 10,000 | $23.18 | $231,800.00 | 84,044 | |
10/30/2015 | Thomas B. Neff | CEO | Sell | 27,000 | $24.06 | $649,620.00 | 3,773,689 | |
10/21/2015 | Thomas F. Kearns, Jr. | Director | Sell | 7,800 | $23.83 | $185,874.00 | 177,736 | |
10/19/2015 | Frank H. Md Valone | insider | Sell | 10,000 | $23.00 | $230,000.00 | 84,044 | |
10/19/2015 | K Peony Yu | VP | Sell | 5,000 | $24.00 | $120,000.00 | 192,904 | |
10/16/2015 | K Peony Yu | VP | Sell | 5,000 | $21.46 | $107,300.00 | 197,904 | |
10/16/2015 | Thomas B. Neff | CEO | Sell | 27,000 | $21.86 | $590,220.00 | 3,800,689 | |
10/2/2015 | Thomas B. Neff | CEO | Sell | 27,000 | $21.59 | $582,930.00 | 3,827,689 | |
10/1/2015 | Frank H. Md Valone | insider | Sell | 10,000 | $21.38 | $213,800.00 | 84,044 | |
9/18/2015 | Thomas B. Neff | CEO | Sell | 27,000 | $29.10 | $785,700.00 | 3,854,689 | |
9/15/2015 | Pat Cotroneo | CFO | Sell | 1,093 | $27.95 | $30,549.35 | 107,498 | |
9/14/2015 | Rory B. Riggs | Director | Sell | 50,000 | $27.61 | $1,380,500.00 | 480,200 | |
9/11/2015 | Miguel Madero | Director | Sell | 20,600 | $27.66 | $569,796.00 | 12,000 | |
9/10/2015 | K Peony Yu | VP | Sell | 1,093 | $27.84 | $30,429.12 | 202,904 | |
9/10/2015 | Pat Cotroneo | CFO | Sell | 7,500 | $27.33 | $204,975.00 | 107,251 | |
9/4/2015 | Thomas B. Neff | CEO | Sell | 13,500 | $22.88 | $308,880.00 | 3,862,751 | |
9/3/2015 | Thomas B. Neff | CEO | Sell | 13,500 | $22.92 | $309,420.00 | 3,866,782 | |
9/1/2015 | Frank H. Md Valone | insider | Sell | 10,000 | $23.58 | $235,800.00 | 84,044 | |
7/23/2015 | Thomas B Neff | CEO | Sell | 27,000 | $24.71 | $667,170.00 | | |
7/20/2015 | Frank H Md Valone | Insider | Sell | 1,000 | $23.70 | $23,700.00 | | |
7/20/2015 | Pat Cotroneo | CFO | Sell | 7,881 | $23.47 | $184,967.07 | | |
7/9/2015 | Thomas B Neff | CEO | Sell | 27,000 | $22.11 | $596,970.00 | | |
7/6/2015 | K Peony Yu | VP | Sell | 5,381 | $22.69 | $122,094.89 | | |
6/25/2015 | Thomas B Neff | CEO | Sell | 27,000 | $23.57 | $636,390.00 | | |
(Data available from 1/1/2013 forward)
FibroGen (NASDAQ FGEN) News Headlines
Source: |
|
Date | Headline |
---|
 | FibroGen (FGEN) Director Kalevi Kurkijarvi Sells 4,000 Shares www.americanbankingnews.com - April 20 at 7:40 PM |
 | FibroGen (FGEN) CEO Thomas B. Neff Sells 39,636 Shares www.americanbankingnews.com - April 19 at 10:10 PM |
 | Form 4 FIBROGEN INC For: Apr 16 Filed by: Yu K Peony www.streetinsider.com - April 19 at 9:10 AM |
 | Insider Selling: FibroGen (FGEN) Insider Sells 7,500 Shares of Stock www.americanbankingnews.com - April 18 at 7:28 PM |
 | FibroGen (FGEN) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 14 at 10:53 PM |
 | FibroGen (FGEN) Expected to Announce Quarterly Sales of $28.23 Million www.americanbankingnews.com - April 14 at 2:02 AM |
 | Brokerages Anticipate FibroGen (FGEN) Will Post Earnings of -$0.51 Per Share www.americanbankingnews.com - April 12 at 9:16 PM |
 | FibroGen (FGEN) Rating Reiterated by Jefferies Group www.americanbankingnews.com - April 12 at 9:00 PM |
 | Stifel Nicolaus Raises FibroGen (FGEN) Price Target to $80.00 www.americanbankingnews.com - April 12 at 9:00 PM |
 | FibroGen (FGEN) Director Sells $279,540.00 in Stock www.americanbankingnews.com - April 11 at 10:37 PM |
 | William Blair Reiterates Outperform Rating for FibroGen (FGEN) www.americanbankingnews.com - April 11 at 6:13 PM |
 | A Look at FibroGen’s Cash Flow Generating Capacity finance.yahoo.com - April 9 at 9:25 AM |
 | Thomas B. Neff Sells 39,636 Shares of FibroGen (FGEN) Stock www.americanbankingnews.com - April 6 at 10:27 PM |
 | Understanding FibroGen’s Research Pipeline finance.yahoo.com - April 6 at 9:35 AM |
 | FibroGen's (FGEN) "Hold" Rating Reaffirmed at Mizuho www.americanbankingnews.com - March 31 at 8:16 PM |
 | FibroGen (FGEN) Given Hold Rating at Mizuho www.americanbankingnews.com - March 29 at 5:16 PM |
 | FibroGen (FGEN) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - March 28 at 1:38 AM |
 | $28.23 Million in Sales Expected for FibroGen (FGEN) This Quarter www.americanbankingnews.com - March 28 at 1:02 AM |
 | Brokerages Expect FibroGen (FGEN) Will Post Earnings of -$0.51 Per Share www.americanbankingnews.com - March 26 at 11:08 PM |
 | Technical Perspectives on Biotech Stocks -- Eyegate Pharma, Fate Therapeutics, FibroGen, and Genocea Biosciences www.prnewswire.com - March 26 at 7:42 AM |
 | FibroGen (FGEN) Upgraded by ValuEngine to "Hold" www.americanbankingnews.com - March 25 at 6:25 PM |
 | FibroGen (FGEN) Lifted to C- at TheStreet www.americanbankingnews.com - March 24 at 3:53 PM |
 | FibroGen (FGEN) Receives Patent for Enhanced Erythropoiesis and Iron Metabolism - StreetInsider.com www.streetinsider.com - March 22 at 4:44 PM |
 | FibroGen Inc (FGEN) Director Roberto Pedro Rosenkranz Sells 1,000 Shares www.americanbankingnews.com - March 16 at 8:32 PM |
 | FibroGen Inc (FGEN) Insider Sells $526,201.20 in Stock www.americanbankingnews.com - March 16 at 7:52 PM |
 | Insider Selling: FibroGen Inc (FGEN) CFO Sells 5,932 Shares of Stock www.americanbankingnews.com - March 16 at 4:08 AM |
 | FibroGen Inc (FGEN) VP Sells $2,221,074.10 in Stock www.americanbankingnews.com - March 15 at 10:10 PM |
 | FibroGen Inc (FGEN) Director Thomas F. Kearns, Jr. Sells 18,000 Shares www.americanbankingnews.com - March 13 at 10:11 PM |
 | Brokerages Anticipate FibroGen Inc (FGEN) Will Post Quarterly Sales of $28.23 Million www.americanbankingnews.com - March 11 at 5:58 AM |
 | FibroGen Inc (FGEN) Director Sells $1,276,953.75 in Stock www.americanbankingnews.com - March 9 at 9:15 PM |
 | Brokerages Expect FibroGen Inc (FGEN) Will Post Earnings of -$0.51 Per Share www.americanbankingnews.com - March 9 at 4:33 PM |
 | FibroGen Inc (FGEN) VP Sells $100,609.28 in Stock www.americanbankingnews.com - March 8 at 9:50 PM |
 | Insider Selling: FibroGen Inc (FGEN) CEO Sells 39,636 Shares of Stock www.americanbankingnews.com - March 8 at 9:15 PM |
 | Landscape Capital Management L.L.C. Purchases Shares of 26,642 FibroGen Inc (FGEN) www.americanbankingnews.com - March 6 at 1:05 PM |
 | FibroGen (FGEN) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - March 5 at 11:14 PM |
 | FibroGen Inc Expected to Post Q1 2018 Earnings of ($0.50) Per Share (FGEN) www.americanbankingnews.com - March 5 at 2:24 AM |
 | ValuEngine Lowers FibroGen (FGEN) to Sell www.americanbankingnews.com - March 4 at 6:42 PM |
 | Teacher Retirement System of Texas Boosts Position in FibroGen Inc (FGEN) www.americanbankingnews.com - March 4 at 7:06 AM |
 | FibroGen Inc (FGEN) Holdings Increased by State of Wisconsin Investment Board www.americanbankingnews.com - March 3 at 8:44 AM |
 | FibroGen Inc (FGEN) Given Average Rating of "Buy" by Analysts www.americanbankingnews.com - March 3 at 1:26 AM |
 | Jefferies Group Analysts Decrease Earnings Estimates for FibroGen Inc (FGEN) www.americanbankingnews.com - March 2 at 2:30 PM |
 | Equities Analysts Issue Forecasts for FibroGen Inc's Q3 2018 Earnings (FGEN) www.americanbankingnews.com - March 2 at 11:33 AM |
 | FibroGen Inc (FGEN) to Post Q1 2018 Earnings of ($0.52) Per Share, William Blair Forecasts www.americanbankingnews.com - March 2 at 9:30 AM |
 | BRIEF-FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment www.reuters.com - March 1 at 5:01 PM |
 | UPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer finance.yahoo.com - March 1 at 5:01 PM |
 | William Blair Comments on FibroGen Inc's Q1 2019 Earnings (FGEN) www.americanbankingnews.com - March 1 at 2:08 PM |
 | BRIEF-Fibrogen Granted Fast Track Designation By U.S. FDA For Pamrevlumab Treatment Of Patients www.reuters.com - March 1 at 8:58 AM |
 | Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer finance.yahoo.com - March 1 at 8:58 AM |
 | FibroGen (FGEN) Given "Outperform" Rating at Leerink Swann www.americanbankingnews.com - March 1 at 12:30 AM |
 | Swiss National Bank Increases Stake in FibroGen Inc (FGEN) www.americanbankingnews.com - February 28 at 5:14 PM |
FibroGen (NASDAQ:FGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
FibroGen (NASDAQ:FGEN) Income Statement, Balance Sheet and Cash Flow Statement
FibroGen (NASDAQ FGEN) Stock Chart for Saturday, April, 21, 2018
Loading chart…